Syndax Pharmaceuticals Reports Q3 EPS USD -0.55 vs IBES Estimate USD -0.49
Syndax Pharmaceuticals reported Q3 EPS of USD -0.55 versus the IBES estimate of USD -0.49.
Related stories
Apple Reports 18% Higher Profit for Fiscal Year, With Record Revenue
M impact | EARNINGS | Nov 03, 2026, 12:42 AM UTC
Palantir Third-Quarter Revenue Surges 96% Year Over Year
Palantir Technologies reported third-quarter revenue growth of 96% year over year.
M impact | EARNINGS | Nov 03, 2026, 12:24 AM UTC
US Futures Gain Slightly Ahead of Midterms
US stock futures edged higher on Tuesday as American voters headed to the polls for the midterm elections, with the Trump administration and Republican Party facing mounting politi
H impact | EARNINGS | Nov 03, 2026, 12:22 AM UTC
Calix Reports Results for Quarter Ended September 30
L impact | EARNINGS | Nov 03, 2026, 12:08 AM UTC
Douglas Dynamics Raises FY2026 EPS and Sales Guidance
Douglas Dynamics raised its FY2026 adjusted EPS guidance to $3.00-$3.40 from $2.90-$3.40 and sales guidance to $770.000M-$805.000M from $765.000M-$805.000M.
M impact | EARNINGS | Nov 03, 2026, 12:03 AM UTC
Empire State Realty Trust Raises FY2026 FFO Guidance
The company raised its FY2026 FFO guidance to $0.77-$0.80 from $0.75-$0.79; the stated estimate is $0.79.
M impact | EARNINGS | Nov 03, 2026, 12:03 AM UTC